Navigation Links
MAP Pharmaceuticals Announces Presentations at the American Thoracic Society International Conference
Date:5/14/2009

MOUNTAIN VIEW, Calif., May 14 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it will present three posters on its Unit Dose Budesonide (UDB) pediatric asthma therapy clinical program and one poster on its MAP0005 formoterol-budesonide combination asthma therapy program at ATS 2009, the International Conference of the American Thoracic Society, in San Diego on May 18, 2009.

The four posters can be viewed on Monday, May 18 between 8:15 a.m. and 4:00 p.m. Pacific Time. The presentations are titled:

  • "Unit Dose Budesonide (UDB): A New Submicron Dispersion of Nebulizable Budesonide Studied in 360 Children 12 Months to 8 Years Old with Mild to Moderate Persistent Asthma--The CASTLE I Study"
  • "A Novel Budesonide Formulation for Nebulization Significantly Improves the Amount of Drug Emitted over One Minute in a Simulated Pediatric Tidal Breathing Model"
  • "A Novel Aqueous Dispersion of Budesonide Significantly Improves the Aerodynamic Particle Sizing Distribution of Budesonide from Various Jet Nebulizers Compared to a Marketed Budesonide Suspension"
  • "Comparative Pharmacodynamics and Pharmacokinetics of MAP0005 (Formoterol-Budesonide Combination Particles Delivered via the Tempo(R) Inhaler) in Mild to Moderate Asthmatics"

Copies of the posters will be available under the Publications tab of the MAP Pharmaceuticals website on Monday, May 18.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
3. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
4. MAP Pharmaceuticals to Present at the Deutsche Bank Securities 34th Annual Health Care Conference
5. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
6. Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention
7. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
8. Onyx Pharmaceuticals to Present at the Deutsche Bank 34th Annual Health Care Conference
9. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
10. Vion Pharmaceuticals Reports 2009 First Quarter Results
11. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... The India Network Foundation, a ... insurance, announces a new pre-existing condition coverage plan: ... the years, India Network members have requested a ... maximums, and duration. The Platinum Comprehensive Plan is ... the valuable coverage and benefits of a PPO ...
(Date:5/20/2013)... Heritage Woods of Gurnee , ... Illinois, is hosting Breakfast and Bingo at 8:30 a.m. ... located at 3775 Grand Ave. in Gurnee, Illinois, serves ... who need some help to maintain their independence. , ... of bingo," says Tammy Temaner-Rosas, Director of Marketing for ...
(Date:5/20/2013)... May 21, 2013 For the ... the Best of Frederick Award in the Professional ... Association (USCA). , The USCA "Best of Local ... the country. Each year, the USCA identifies companies ... in their local community and business category. These ...
(Date:5/20/2013)... May 20, 2013 Recent environmental ... of using green and sustainable inputs in packaging ... implemented regulations to promote the use of sustainable ... and Labelling Services industry . “Tax subsidies and ... says IBISWorld industry analyst Deonta Smith. “For example, ...
(Date:5/20/2013)... Dr. Robert Mokbel is one of the ... the Laser Assisted New Attachment Procedure, a laser ... disease. LANAP may help many Fountain Valley residents who ... the jawbone support necessary to support dental implants. , ... tartar in the mouth. Daily oral hygiene activities typically ...
Breaking Medicine News(10 mins):Health News:Indian Network announces Platinum Comprehensive Visitor Health Insurance Plan with Pre-existing Condition Choices for Visitors on Short Term Trip to the United States 2Health News:Indian Network announces Platinum Comprehensive Visitor Health Insurance Plan with Pre-existing Condition Choices for Visitors on Short Term Trip to the United States 3Health News:Heritage Woods of Gurnee Affordable Assisted Living Community to Host Breakfast and Bingo 2Health News:A2LA Receives 2013 Best of Frederick Award 2Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Fountain Valley, Ca Gum Disease Patients with Missing Teeth Can Now Receive Laser Gum Surgery from Dr. Robert Mokbel for Success with Dental Implants 2
... of Minnesota scientists anti-angiogenics are compounds that are very ... molecules which cut of the blood supply to the ... The study results appear in the Journal of the ... drugs that increases the potential for good, effective treatment ...
... monitoring data human welfare, spread of infectious disease and food ... to acquire the proper balance between ecological systems//. ... has used a satellite imagery to enable the study of ... effect on human health and food security. ,Doug ...
... of Kansas State University, Doug Goodin, makes use of ... and land cover //changes on human health and food ... sensing with other types of data, to monitor and ... scientists he recently discussed this subject at the workshop, ...
... to zero in (on) the modalities of a drug, capable ... Clinical trials on animal models have revealed the capacity of ... in charge of energy production., ,'Many drugs block ... Glick, who is the Werner E. Bachmann Collegiate Professor of ...
... NHS can be freed from its’ problems, if privatization ... are implemented. // It is amply clear that the ... worse for the deprived and under privileged sections of ... low morale among Doctors and NHS staff. Quality of ...
... BARACLUDE? (entecavir) for the treatment of chronic hepatitis B ... General of India. ,BARACLUDE (entecavir) is indicated ... in adults with evidence of active viral replication and ... or AST) or histologically active disease. ,BARACLUDE? ...
Cached Medicine News:Health News:Ecological Changes affects human health, food security 2Health News:Satellite Imagery to monitor the Social Impact Of Geographical Changes 2Health News:Autoimmune disorders studied in detail by U-M researchers. 2Health News:India Approves Baraclude? (entecavir) For ,Treatment Of Chronic HEPATITIS B 2
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ...   Summary ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, ... secondary analysis of its double-blind, randomized, controlled Phase ... a gene therapy product designed to deliver the ... analysis identified a more robust response to CERE-120 ... to treatment relative to those diagnosed 10 years ...
(Date:5/21/2013)... Calif. , May 21, 2013 /PRNewswire/ ... ), a specialty pharmaceutical company focused on ... for the treatment of acute and breakthrough ... in a placebo-controlled Phase 3 study of ... analgesia) System (NanoTab System), the primary efficacy ...
Breaking Medicine Technology:Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
... next generation system for ... the power of automation ... laboratory. As many as ... loaded and analyzed in ...
Medicine Products: